Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 317-325

  Konya, Hiroyuki ^a   Katsuno, Tomoyuki ^b   Tsunoda, Taku ^a   Yano, Yuzo ^a   Kamitani, Mai ^a   Miuchi, Masayuki ^b   Hamaguchi, Tomoya ^b   Miyagawa, Jun Ichiro ^b   Namba, Mitsuyoshi ^b  

^a Department of Internal Medicine   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Combination therapy; Mitiglinide; Postprandial hyperglycemia; Type 2 diabetes mellitus; Voglibose

Indexed keywords

ACARBOSE; ALOGLIPTIN; GLIBENCLAMIDE; GLIMEPIRIDE; MIGLITOL; MITIGLINIDE; NATEGLINIDE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; SITAGLIPTIN; VILDAGLIPTIN; VOGLIBOSE;

DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84884216158     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S36046     Document Type: Review

References (52)

1. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes. 1974;23(2):105-111.
2. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60(3):473-485.
3. Ebenbichler CF, Kirchmair R, Egger C, Patsch JR. Postprandial state and atherosclerosis. Curr Opin Lipidol. 1995;6(5):286-290.
4. Lefèbvre PJ, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diabet Med. 1998;15(Suppl 4):S63-S68.
5. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev. 2000;16(2):125-132.
6. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001;44(12):2107-2114.
7. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21(3):360-367.
8. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet. 1999; 354(9179):617-621.
9. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486-494.
10. Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ. 2005;172(2):213-226.
11. Harada S, Nomura M, Nakaya Y, Ito S. Nateglinide with glibencl-amide examination using the respiratory quotient (RQ). J Med Invest. 2006;53(3-4):303-309.
12. Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P. Effcacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract. 2002;55(2):99-103.
13. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373(9675): 1607-1614.
14. Malaisse WJ. Mitiglinide: a rapid-and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother. 2008;9(15):2691-2698.
15. Gao X; Mitiglinide Versus Nateglinide Comparison Study Group. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res. 2009;37(3):812-821.
16. Konya H, Miuchi M, Konishi K, et al. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. J Int Med Res. 2009;37(6):1904-1912.
17. Phillippe HM, Wargo KA. Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2010;44(10): 1615-1623.
18. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Combination therapy with mitiglinide and voglibose improves glyce-mic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother. 2010;11(2):169-176.
19. Katsuno T, Wantanabe N, Nagai E, et al. Comparison of effcacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus. J Diabetes Investig. 2011;2(3):204-209.
20. Inoue M. Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fxed-dose combination in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2012;13(16): 2257-2268.
21. Pharmaceutical and Medical Devices Agency. Deliberation Report. March 23, 2011 (Voglibose/Mitiglinide Tablets). 2011.
22. Mogami H, Shibata H, Nobusawa R, et al. Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell. Eur J Pharmacol. 1994;269(3): 293-298.
23. Reimann F, Proks P, Ashcroft FM. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J Pharmacol. 2001;132(7): 1542-1548.
24. Mori Y, Ojima K, Fuujimori Y, et al. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyc-eride elevation in prediabetic and diabetic OLETF rats. Endocrine. 2006;29(2):309-315.
25. Toyoda Y, Mizutani K, Miwa I. Increase in hepatic glucose metabolism by mitiglinide calcium dehydrate-induced translocation of glucokinase from the nuclear to the cytoplasm. Prog Med. 2008;28:1951-1958. Japanese.
26. GLUFAST® tablets [package insert] (10th edition). Tokyo, Japan: Kissei Pharmaceutical Co, Ltd; 2012.
27. FASTIC® tablets [package insert] (24th edition). Tokyo, Japan: Mochida Pharmaceutical Co, Ltd; 2012.
28. SUREPOST® tablets [package insert] (4th edition). Osaka, Japan: Dainippon Sumitomo Pharma Co, Ltd; 2013.
29. Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001;431(1):119-125.
30. Ohnota H, Koizumi T, Tsutsumi N, Kobayashi M, Inoue S, Sato F. Novel rapid-and short-acting hypoglycemic agent, a calcium(2 s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther. 1994;269(2):489-495.
31. Assaloni R, Da Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and infammation in type 2 diabetic patients. Diabetologia. 2005;48(9):1919-1924.
32. Thisted H, Johnsen S P, Rungby J. Sulfonylureas and the risk of myo-cardial infarction. Metabolism. 2006;55(5 Suppl 1):S16-S19.
33. Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes. 2004;53(Suppl 3): S156-S164.
34. Abdelmoneim AS, Hasenbank SE, Seubert JM, Brocks DR, Light PE, Simpson SH. Variations in tissue selectivity amongst insulin secre-tagogues: a systematic review. Diabetes Obes Metab. 2012;14(2): 130-138.
35. Ogawa K, Ikewaki K, Taniguchi I, et al. Mitiglinide, a novel oral hypoglycemic agent, preserves the cardioprotective effect of ischemic preconditioning in isolated perfused rat hearts. Int Heart J. 2007;48(3): 337-345.
36. Maruyama I, Tomiyama Y, Maruyama K, et al. Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts. Eur J Pharmacol. 2006;531(1-3):194-200.
37. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol. 2010;9:12.
38. Yamaoka-Tojo M, Tojo T, Izumi T. Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. Curr Vasc Pharmacol. 2008;6(4):271-281.
39. Yamaoka-Tojo M, Tojo T, Kosugi R, et al. Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids Health Dis. 2009;8:41.
40. Kitasato L, Tojo T, Hatakeyama Y, Kameda R, Hashikata T, Yamaoka-Tojo M. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide. Cardiovasc Diabetol. 2012; 11:79.
41. Kamitani M, Konya H, Miuchi M, et al. Effects of mitiglinide on incretin hormone responses in a case of impaired glucose tolerance following total gastrectomy with Roux en Y rebuilding. J Diabetes Invest. 2012;3(Suppl 1):S237.
42. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470-512.
43. Ono Y, Kameda H, Cho K Y. Mitiglinide/voglibose fxed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2013;14(4):361-370.
44. Moritoh Y, Takeuchi K, Hazama M. Chronic administration of vogli-bose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipep-tidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther. 2009;329(2):669-676.
45. Cani PD, Hoste S, Guiot Y, Delzenne NM. Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. Br J Nutr. 2007;98(1):32-37.
46. Kosaka K, Hagura R, Kuzuya T. Insulin responses in equivocal and defnite diabetes, with special reference to subjects who had mild glucose intolerance but later developed defnite diabetes. Diabetes. 1977;26(10):944-952.
47. Mitsui R, Fukushima M, Nishi Y, et al. Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men. Metab Clin Exp. 2006;55(1):53-58.
48. Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia. 1984;26(1):44-49.
49. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab. 2011;12(1):57-69.
50. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocr J. 2010;57(7):579-586.
51. Tschöpe D, Bramlage P, Binz C, et al. Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry. Cardiovasc Diabetol. 2011;10:66.
52. Ito M, Abe M, Okada K, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J. 2011;58(11):979-987.